secwatch.observer — SEC 8-K summary
======================================

Issuer:     Marker Therapeutics, Inc. (MRKR)
CIK:        0001094038
Form:       8-K
Filed at:   2023-05-08T23:59:59+00:00
Accession:  0001104659-23-056863
Event type: leadership
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Marker Therapeutics names Monic Stuart, M.D., as new CMO; she brings 20+ years drug development experience
--------------------------------------------------------------------------------

- Dr. Stuart appointed CMO effective May 8, 2023; will oversee multiTAA-specific T cell pipeline including MT-401 Phase 2 ARTEMIS study.
- Over 20 years experience; previously interim CMO at multiple biotechs, VP Clinical Development at Geron, Senior Medical Director at Genentech.
- She is a transplant physician with expertise in AML and lymphoma, aligning with Marker's prioritized clinical programs.
- Dr. Stuart will lead clinical strategy for MT-401 in AML and MT-601 in non-Hodgkin lymphoma and pancreatic cancer.
- CEO Juan Vera cited her deep industry experience and clinical background as key to advancing pipeline.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1094038/000110465923056863/0001104659-23-056863-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1094038/000110465923056863/tm2314958d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-056863

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer